Header Logo

ELIZABETH A GRIMM

TitleProfessor
InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chattopadhyay C, Roszik J, Bhattacharya R, Alauddin M, Mahmud I, Yadugiri S, Ali MM, Khan FS, Prabhu VV, Lorenzi P, Burton E, Morey RR, Lazcano R, Davies MA, Patel SP, Grimm EA. Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. bioRxiv. 2024 Jan 15. PMID: 38293232; PMCID: PMC10827043.
      Citations:    
    2. Fukuda Y, Kim SH, Bustos MA, Cho SN, Roszik J, Burks JK, Kim H, Hoon DSB, Grimm EA, Ekmekcioglu S. Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun. 2023 07; 3(7):1397-1408. PMID: 37529399; PMCID: PMC10389052.
      Citations:    Translation:AnimalsCells
    3. Chattopadhyay C, Bhattacharya R, Roszik J, Khan FS, Wells GA, Villanueva H, Qin Y, Bhattacharya R, Patel SP, Grimm EA. Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers (Basel). 2022 Dec 19; 14(24). PMID: 36551732; PMCID: PMC9777326.
      Citations: 1     
    4. Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu S. Correction: Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 May 02; 13(5):422. PMID: 35501311; PMCID: PMC9061713.
      Citations:    Fields:    
    5. Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, Burks JK, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu S. Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 02 04; 13(2):117. PMID: 35121729; PMCID: PMC8816905.
      Citations: 1     Fields:    Translation:HumansCells
    6. Ding Z, Ogata D, Roszik J, Qin Y, Kim SH, Tetzlaff MT, Lazar AJ, Davies MA, Ekmekcioglu S, Grimm EA. iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Front Oncol. 2021; 11:631766. PMID: 33643925; PMCID: PMC7907506.
      Citations: 2     
    7. Ogata D, Roszik J, Oba J, Kim SH, Bassett RL, Haydu LE, Tanese K, Grimm EA, Ekmekcioglu S. The Expression of CD74-Regulated Inflammatory Markers in Stage IV Melanoma: Risk of CNS Metastasis and Patient Survival. Cancers (Basel). 2020 Dec 14; 12(12). PMID: 33327409; PMCID: PMC7764866.
      Citations: 2     
    8. Saif MW, Rajagopal S, Caplain J, Grimm E, Serebrennikova O, Das M, Tsichlis PN, Martell R. A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors. Cancer Chemother Pharmacol. 2019 12; 84(6):1323-1331. PMID: 31583436.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    9. Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE. Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Invest Ophthalmol Vis Sci. 2019 10 01; 60(13):4187-4195. PMID: 31596927; PMCID: PMC6785781.
      Citations: 9     Fields:    Translation:HumansCells
    10. Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN, Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni D, Markel G, Leibowitz-Amit R. TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma. Cancer Immunol Immunother. 2019 Sep; 68(9):1493-1500. PMID: 31501955.
      Citations: 8     Fields:    Translation:HumansCells
    11. Kim SH, Roszik J, Cho SN, Ogata D, Peng W, Menter DG, Ekmekcioglu S, Grimm EA, Milton DR. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. 2019 03 01; 25(5):1650-1663. PMID: 30538110; PMCID: PMC6397703.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    12. Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 12; 2:1-12. PMID: 30652536; PMCID: PMC6873994.
      Citations: 3     Fields:    Translation:Humans
    13. McKean M, Oba J, Ma J, Roth KG, Wang WL, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, Lazar AJ, Woodman SE, Macedo MP. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol. 2019 03; 139(3):728-731. PMID: 30798855.
      Citations: 4     Fields:    Translation:Humans
    14. Dal Yontem F, Kim SH, Ding Z, Grimm E, Ekmekcioglu S, Akcakaya H. Mitochondrial dynamic alterations regulate melanoma cell progression. J Cell Biochem. 2018 Sep 06. PMID: 30256441.
      Citations: 8     Fields:    
    15. Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol. 2018; 2018. PMID: 30094412; PMCID: PMC6080631.
      Citations: 9     Fields:    
    16. Kim SH, Roszik J, Grimm EA, Ekmekcioglu S. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. Front Oncol. 2018; 8:67. PMID: 29616189; PMCID: PMC5864849.
      Citations: 45     
    17. Qin Y, Ekmekcioglu S, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J, Forget MA. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689. PMID: 28670312; PMCID: PMC5473350.
      Citations: 28     Fields:    
    18. Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. PLoS One. 2017; 12(4):e0176763. PMID: 28453553; PMCID: PMC5409143.
      Citations: 17     Fields:    Translation:HumansCells
    19. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA, Forget MA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2. PMID: 28819565; PMCID: PMC5557036.
      Citations: 64     
    20. Esmaeli B, Ellerhorst JA, Lyons GR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C, Oba J, Milton DR. Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression. Melanoma Res. 2017 04; 27(2):126-133. PMID: 28118269.
      Citations: 2     Fields:    Translation:Humans
    21. Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia. 2017 03; 19(3):237-249. PMID: 28254151; PMCID: PMC6197604.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    22. Ekmekcioglu S, Grimm EA, Roszik J. Targeting iNOS to increase efficacy of immunotherapies. Hum Vaccin Immunother. 2017 05 04; 13(5):1105-1108. PMID: 28121247; PMCID: PMC5443387.
      Citations: 21     Fields:    Translation:HumansCells
    23. Bailey P, Chang DK, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J, Forget MA. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep. 2016 10 20; 6:35848. PMID: 27762323; PMCID: PMC5071896.
      Citations: 64     Fields:    Translation:HumansCells
    24. Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunol Res. 2016 11; 4(11):983-994. PMID: 27697858.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    25. Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454. PMID: 27458138; PMCID: PMC5079683.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    26. Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7. PMID: 24977319; PMCID: PMC4948741.
      Citations: 2     Fields:    Translation:Humans
    27. Kim SH, Hashimoto Y, Cho SN, Roszik J, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA, Milton DR. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res. 2016 May; 29(3):297-308. PMID: 26801201; PMCID: PMC4840087.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    28. Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016 08 01; 122(15):2299-312. PMID: 26991400; PMCID: PMC5567680.
      Citations: 100     Fields:    Translation:Humans
    29. Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA. Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore). 2016 Mar; 95(11):e3073. PMID: 26986135; PMCID: PMC4839916.
      Citations: 22     Fields:    Translation:Humans
    30. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA, Milton DR. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24. PMID: 26783288; PMCID: PMC4911309.
      Citations: 25     Fields:    Translation:Humans
    31. Grimm EA. Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance. Crit Rev Oncog. 2016; 21(1-2):57-63. PMID: 27481002; PMCID: PMC5796770.
      Citations: 2     Fields:    Translation:HumansCells
    32. Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L. Dual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27. PMID: 26450788; PMCID: PMC4670809.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    33. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2901. PMID: 26178706.
      Citations: 8     Fields:    
    34. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2775-2784. PMID: 26039541; PMCID: PMC4640965.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    35. Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res. 2015 May; 28(3):357-9. PMID: 25515650.
      Citations: 19     Fields:    Translation:HumansCells
    36. Qin Y, Oba J, Ding Z, Ekmekcioglu S, Grimm EA, Milton DR, Liz?e G. Inflammatory IL-1?-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res. 2015 Mar; 28(2):236-9. PMID: 25546243.
      Citations: 3     Fields:    Translation:HumansCells
    37. Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol. 2014 Aug; 7(4):484-92. PMID: 24969538; PMCID: PMC4202801.
      Citations: 20     
    38. Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014; 9(2):e83957. PMID: 24551032; PMCID: PMC3923717.
      Citations: 16     Fields:    Translation:HumansCells
    39. Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG, Milton DR. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 2014 Feb 15; 74(4):1067-78. PMID: 24398473; PMCID: PMC3960077.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    40. Greene VR, Wilson H, Pfent C, Roethele J, Carwile J, Qin Y, Grimm E, Ellerhorst JA. Expression of leptin and iNOS in oral melanomas in dogs. J Vet Intern Med. 2013 Sep-Oct; 27(5):1278-82. PMID: 24033424; PMCID: PMC3955362.
      Citations: 5     Fields:    Translation:Animals
    41. Grimm EA, Sikora AG, Ekmekcioglu S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res. 2013 Oct 15; 19(20):5557-63. PMID: 23868870; PMCID: PMC3873873.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    42. Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res. 2013 May; 26(3):422-5. PMID: 23360207; PMCID: PMC3721512.
      Citations: 1     Fields:    Translation:HumansCells
    43. Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol. 2013 Jul; 133(7):1813-21. PMID: 23407396; PMCID: PMC3660504.
      Citations: 28     Fields:    Translation:HumansCells
    44. Qin Y, Deng W, Ekmekcioglu S, Grimm EA. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell Melanoma Res. 2013 Jan; 26(1):97-112. PMID: 23020131; PMCID: PMC3919534.
      Citations: 13     Fields:    Translation:HumansCells
    45. Khalili JS, Liu S, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Rodr?guez-Cruz TG, Liz?e G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40. PMID: 22850568; PMCID: PMC3463754.
      Citations: 142     Fields:    Translation:HumansCells
    46. Shirley SH, Grimm EA, Kusewitt DF. Ultraviolet radiation and the slug transcription factor induce proinflammatory and immunomodulatory mediator expression in melanocytes. J Skin Cancer. 2012; 2012:410925. PMID: 22745913; PMCID: PMC3382223.
      Citations: 3     
    47. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833. PMID: 22558101; PMCID: PMC3338819.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    48. Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, Kusewitt DF. Slug expression during melanoma progression. Am J Pathol. 2012 Jun; 180(6):2479-89. PMID: 22503751; PMCID: PMC3378849.
      Citations: 32     Fields:    Translation:HumansCells
    49. Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wang LE. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75. PMID: 22198560; PMCID: PMC3296883.
      Citations: 10     Fields:    Translation:HumansCells
    50. Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger AB. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44. PMID: 22488042; PMCID: PMC3359889.
      Citations: 12     Fields:    Translation:HumansCells
    51. Jen EY, Poindexter NJ, Farnsworth ES, Grimm EA. IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. Melanoma Res. 2012 Feb; 22(1):19-29. PMID: 22027907; PMCID: PMC3253989.
      Citations: 7     Fields:    Translation:HumansCells
    52. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer. 2012 Jul 15; 131(2):E56-65. PMID: 22020736; PMCID: PMC3337366.
      Citations: 26     Fields:    Translation:HumansCells
    53. Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer. 2012 Aug 15; 131(4):891-901. PMID: 21953496; PMCID: PMC3269542.
      Citations: 20     Fields:    Translation:HumansCells
    54. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Poindexter N, Grimm EA, Liz?e G. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res. 2011 Nov; 9(11):1537-50. PMID: 21954434; PMCID: PMC3387749.
      Citations: 43     Fields:    Translation:HumansCells
    55. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, GenoMEL Investigators, MacGregor S, Hayward NK, Martin NG, Duffy DL, Q-Mega Investigators, Mann GJ, Cust A, Hopper J, AMFS Investigators, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011 Dec 15; 20(24):5012-23. PMID: 21926416; PMCID: PMC3298855.
      Citations: 119     Fields:    Translation:HumansCells
    56. Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A, Newman RA, Grimm EA. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutr Cancer. 2011; 63(6):940-9. PMID: 21745040.
      Citations: 7     Fields:    Translation:HumansCells
    57. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res. 2011 Feb; 21(1):44-56. PMID: 20216471; PMCID: PMC2945428.
      Citations: 10     Fields:    Translation:HumansCells
    58. Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, Ramesh R. Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J Drug Deliv. 2011; 2011:465845. PMID: 21490751; PMCID: PMC3065904.
      Citations: 6     
    59. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35. PMID: 20975100; PMCID: PMC3022950.
      Citations: 97     Fields:    Translation:Humans
    60. Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA. IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes. Exp Dermatol. 2010 Aug; 19(8):714-22. PMID: 20545760; PMCID: PMC3161412.
      Citations: 20     Fields:    Translation:HumansCells
    61. Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15. PMID: 20655738; PMCID: PMC2987546.
      Citations: 5     Fields:    Translation:Humans
    62. Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, Grimm EA. Promotion of melanoma growth by the metabolic hormone leptin. Oncol Rep. 2010 Apr; 23(4):901-7. PMID: 20204272; PMCID: PMC3158136.
      Citations: 19     Fields:    Translation:HumansCells
    63. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44. PMID: 20215556; PMCID: PMC2858983.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    64. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol. 2009 Jun; 129(6):1483-8. PMID: 19037234; PMCID: PMC2741006.
      Citations: 21     Fields:    Translation:HumansCells
    65. Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA. Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma. J Urol. 2009 Mar; 181(3):1028-34; discussion 1034. PMID: 19150565; PMCID: PMC2739625.
      Citations: 7     Fields:    Translation:Humans
    66. Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008 Dec; 7(12):3842-51. PMID: 19056673; PMCID: PMC2653264.
      Citations: 20     Fields:    Translation:HumansCells
    67. Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51. PMID: 18563783; PMCID: PMC2937220.
      Citations: 26     Fields:    Translation:Humans
    68. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32. PMID: 19002459; PMCID: PMC2674523.
      Citations: 42     Fields:    Translation:HumansCells
    69. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68. PMID: 18794085; PMCID: PMC2583362.
      Citations: 68     Fields:    Translation:AnimalsCells
    70. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5. PMID: 18626307; PMCID: PMC3880193.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    71. Uffort DG, Grimm EA, Ellerhorst JA. NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol. 2009 Jan; 129(1):148-54. PMID: 18668140; PMCID: PMC2758038.
      Citations: 12     Fields:    Translation:HumansCells
    72. Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EA. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine. 2008 Jul; 43(1):34-44. PMID: 18511292; PMCID: PMC2582834.
      Citations: 15     Fields:    Translation:HumansCells
    73. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84. PMID: 18183598; PMCID: PMC2938035.
      Citations: 26     Fields:    Translation:Humans
    74. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide. 2008 Sep; 19(2):133-7. PMID: 18472017; PMCID: PMC2577016.
      Citations: 24     Fields:    Translation:HumansCells
    75. Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8. PMID: 18049450; PMCID: PMC2938047.
      Citations: 10     Fields:    Translation:HumansCells
    76. Li C, Hu Z, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8. PMID: 17328085.
      Citations: 6     Fields:    Translation:Humans
    77. Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemother Pharmacol. 2007 Oct; 60(5):625-33. PMID: 17195067.
      Citations: 4     Fields:    Translation:HumansCells
    78. Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm EA. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res. 2006 Dec; 26(12):877-86. PMID: 17238830.
      Citations: 7     Fields:    Translation:HumansCells
    79. Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32. PMID: 17164380.
      Citations: 36     Fields:    Translation:HumansCells
    80. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80. PMID: 16990805.
      Citations: 19     Fields:    Translation:Humans
    81. Hwu P, Bedikian AY, Grimm EA. Challenges of chemosensitivity testing. Clin Cancer Res. 2006 Sep 15; 12(18):5258-9. PMID: 17000655.
      Citations: 2     Fields:    Translation:Humans
    82. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006 Aug 15; 119(4):861-6. PMID: 16557582.
      Citations: 62     Fields:    Translation:Humans
    83. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006 Jul; 8(3):261-79. PMID: 16775224; PMCID: PMC1871955.
      Citations: 277     Fields:    Translation:HumansCells
    84. Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Sutton RB, Poindexter N, Grimm EA, Chada S. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother. 2007 Feb; 56(2):205-15. PMID: 16710719.
      Citations: 26     Fields:    Translation:HumansCells
    85. Li C, Liu Z, Wang LE, Strom SS, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901. PMID: 16621887.
      Citations: 26     Fields:    Translation:Humans
    86. Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63. PMID: 16538172.
      Citations: 17     Fields:    Translation:Humans
    87. Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB. Innate immune functions of microglia isolated from human glioma patients. J Transl Med. 2006 Mar 30; 4:15. PMID: 16573834; PMCID: PMC1501057.
      Citations: 39     Fields:    
    88. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene. 2006 Jun 29; 25(28):3956-62. PMID: 16474847.
      Citations: 12     Fields:    Translation:HumansCells
    89. Poindexter NJ, Walch ET, Chada S, Grimm EA. Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. J Leukoc Biol. 2005 Sep; 78(3):745-52. PMID: 16000394.
      Citations: 25     Fields:    Translation:HumansCells
    90. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, Zheng M. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther. 2005 May; 11(5):724-33. PMID: 15851011.
      Citations: 34     Fields:    Translation:HumansCells
    91. Ekmekcioglu S, Tang CH, Grimm EA. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets. 2005 Mar; 5(2):103-15. PMID: 15810875.
      Citations: 15     Fields:    Translation:HumansAnimals
    92. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan; 11(1):160-72. PMID: 15585417.
      Citations: 78     Fields:    Translation:HumansCellsCTClinical Trials
    93. Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu S. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004 Dec; 10(6):1085-95. PMID: 15564140.
      Citations: 39     Fields:    Translation:HumansCells
    94. Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA. HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC. Urologe A. 2004 Sep; 43 Suppl 3:S137. PMID: 15148575.
      Citations:    Fields:    Translation:Humans
    95. Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, Johnson MM, Gunn DC, Yekell S, Grimm EA. Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res. 2004 Aug 15; 10(16):5531-6. PMID: 15328193.
      Citations: 8     Fields:    Translation:HumansCells
    96. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer. 2004 Aug 01; 101(3):596-603. PMID: 15274073.
      Citations: 3     Fields:    Translation:Humans
    97. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 2004; 6(4):R408-15. PMID: 15217509; PMCID: PMC468660.
      Citations: 28     Fields:    Translation:HumansCells
    98. Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res. 2004 Jun; 14(3):165-71. PMID: 15179184.
      Citations: 45     Fields:    Translation:HumansCells
    99. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM, Po?ndexter N. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004 May; 4(5):649-67. PMID: 15120650.
      Citations: 39     Fields:    Translation:Humans
    100. Tawa P, Hell K, Giroux A, Grimm E, Han Y, Nicholson DW, Xanthoudakis S. Catalytic activity of caspase-3 is required for its degradation: stabilization of the active complex by synthetic inhibitors. Cell Death Differ. 2004 Apr; 11(4):439-47. PMID: 14713960.
      Citations: 37     Fields:    Translation:HumansCells
    101. Sieger KA, Mhashilkar AM, Stewart A, Sutton RB, Strube RW, Chen SY, Pataer A, Swisher SG, Grimm EA, Ramesh R, Chada S. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther. 2004 Mar; 9(3):355-67. PMID: 15006602.
      Citations: 25     Fields:    Translation:HumansCells
    102. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem. 2004 Jan 02; 279(1):288-98. PMID: 14576150.
      Citations: 32     Fields:    Translation:HumansCells
    103. Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM, Grimm EA. High prevalence of hypothyroidism among patients with cutaneous melanoma. Oncol Rep. 2003 Sep-Oct; 10(5):1317-20. PMID: 12883700.
      Citations: 7     Fields:    Translation:Humans
    104. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquoi A, Dumoutier L, Grimm EA, Renauld JC, Kotenko S, Chada S, Boquio A. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003 Aug 15; 63(16):5105-13. PMID: 12941841.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    105. Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, Saito Y, Hunt KK, Grimm EA, Roth JA, Meyn RE, Ramesh R, Chada S. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther. 2003 Aug; 8(2):207-19. PMID: 12907143.
      Citations: 24     Fields:    Translation:HumansCells
    106. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT, Dent P. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S23-37. PMID: 14508078.
      Citations: 73     Fields:    Translation:HumansAnimalsCells
    107. Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA. Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J Urol. 2003 Jun; 169(6):2084-8. PMID: 12771724.
      Citations: 2     Fields:    Translation:Humans
    108. Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EA. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther. 2003 Jan; 2(1):9-17. PMID: 12533668.
      Citations: 16     Fields:    Translation:HumansCells
    109. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther. 2002 Oct; 1(12):1009-17. PMID: 12481423.
      Citations: 14     Fields:    Translation:HumansCells
    110. Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93. PMID: 12095976.
      Citations: 9     Fields:    Translation:Humans
    111. Ellerhorst JA, Cooksley CD, Grimm EA. Autoimmunity and hypothyroidism in patients with uveal melanoma. Melanoma Res. 2001 Dec; 11(6):633-7. PMID: 11725210.
      Citations: 9     Fields:    Translation:Humans
    112. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer. 2001 Oct 01; 94(1):54-9. PMID: 11668478.
      Citations: 27     Fields:    Translation:HumansCells
    113. Yergey JA, Trimble LA, Silva J, Chauret N, Li C, Therien M, Grimm E, Nicoll-Griffith DA. In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. Drug Metab Dispos. 2001 May; 29(5):638-44. PMID: 11302928.
      Citations: 2     Fields:    Translation:AnimalsCells
    114. Licato LL, Prieto VG, Grimm EA. A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels. In Vitro Cell Dev Biol Anim. 2001 Mar; 37(3):121-6. PMID: 11370802.
      Citations: 8     Fields:    Translation:HumansCells
    115. Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol. 2001 Mar; 8(2):116-22. PMID: 11258775.
      Citations: 16     Fields:    Translation:Humans
    116. Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Roy P, Wang Z, Prasit P, Zamboni R, Young RN, Brideau C, Chan CC, Mancini J, Riendeau D, Nicoll-Griffith DA, L?ger S, Th?rien M. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). Bioorg Med Chem Lett. 2000 Dec 04; 10(23):2683-6. PMID: 11128651.
      Citations: 5     Fields:    Translation:HumansAnimals
    117. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol. 2000 Dec; 1(6):496-501. PMID: 11101871.
      Citations: 195     Fields:    Translation:HumansAnimalsCells
    118. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000 Dec; 6(12):4768-75. PMID: 11156233.
      Citations: 61     Fields:    Translation:Humans
    119. Caudell EG, Caudell JJ, Tang CH, Yu TK, Frederick MJ, Grimm EA. Characterization of human copine III as a phosphoprotein with associated kinase activity. Biochemistry. 2000 Oct 24; 39(42):13034-43. PMID: 11041869.
      Citations: 15     Fields:    Translation:HumansCells
    120. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000 Oct; 6(10):3895-903. PMID: 11051235.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    121. Yu TK, Caudell EG, Smid C, Grimm EA. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol. 2000 Jun 15; 164(12):6244-51. PMID: 10843677.
      Citations: 36     Fields:    Translation:HumansCells
    122. Li CS, Black WC, Brideau C, Chan CC, Charleson S, Cromlish WA, Claveau D, Gauthier JY, Gordon R, Greig G, Grimm E, Guay J, Lau CK, Riendeau D, Visco DM, Wong E, Xu L, Prasit P, Th?rien M. A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett. 1999 Nov 15; 9(22):3181-6. PMID: 10576684.
      Citations: 3     Fields:    Translation:AnimalsCells
    123. Licato LL, Grimm EA. Multiple interleukin-2 signaling pathways differentially regulated by microgravity. Immunopharmacology. 1999 Nov; 44(3):273-9. PMID: 10598884.
      Citations: 10     Fields:    Translation:HumansCells
    124. Roy P, Boyce S, Brideau C, Chan CC, Charleson S, Gordon R, Grimm E, Guay J, Li CS, Riendeau D, Visco D, Wang Z, Webb J, Xu LJ, Prasit P, Leblanc Y, L?ger S. SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorg Med Chem Lett. 1999 Aug 02; 9(15):2207-12. PMID: 10465547.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    125. Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-Schaub L, Buzaid AC, Grimm EA. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res. 1999 Jun; 9(3):261-72. PMID: 10465582.
      Citations: 7     Fields:    Translation:HumansCells
    126. Robinson EK, Sneige N, Grimm EA. Correlation of interleukin 6 with interleukin 1alpha in human mammary tumours, but not with oestrogen receptor expression. Cytokine. 1998 Dec; 10(12):970-6. PMID: 10049521.
      Citations: 1     Fields:    Translation:HumansCells
    127. Woods KV, Adler-Storthz K, Clayman GL, Francis GM, Grimm EA. Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6/E7. Cancer Res. 1998 Jul 15; 58(14):3142-9. PMID: 9679982.
      Citations: 10     Fields:    Translation:HumansCells
    128. Woods KV, El-Naggar A, Clayman GL, Grimm EA. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res. 1998 Jul 15; 58(14):3132-41. PMID: 9679981.
      Citations: 28     Fields:    Translation:HumansCells
    129. Robinson EK, Grau AM, Evans DB, Smid CM, Chiao PJ, Abbruzzese JL, Grimm EA. Cell cycle regulation of human pancreatic cancer by tamoxifen. Ann Surg Oncol. 1998 Jun; 5(4):342-9. PMID: 9641456.
      Citations: 3     Fields:    Translation:HumansCells
    130. Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. 1998 Apr; 8(2):149-55. PMID: 9610868.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    131. Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Res. 1998 Apr; 8(2):145-8. PMID: 9610867.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    132. Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, Grimm EA, Roth JA. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. 1998 Feb; 5(2):189-95. PMID: 9578838.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    133. Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997 Aug; 15(8):2826-31. PMID: 9256125.
      Citations: 15     Fields:    Translation:HumansCells
    134. Frederick M, Grimm E, Krohn E, Smid C, Yu TK. Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. J Interferon Cytokine Res. 1997 Aug; 17(8):435-47. PMID: 9282823.
      Citations: 4     Fields:    Translation:HumansCells
    135. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study. J Immunother. 1997 Jan; 20(1):79-87. PMID: 9101417.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    136. Frederick MJ, Yu TK, Krohn EG, Johnston DA, Grimm EA. Protein tyrosine kinase inhibition blocks granule exocytosis and cytolytic function of lymphokine-activated killer cells. Immunopharmacology. 1996 Nov; 35(2):83-102. PMID: 8956972.
      Citations: 1     Fields:    Translation:HumansCells
    137. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol. 1996 Aug; 105(2):344-52. PMID: 8706344; PMCID: PMC2200505.
      Citations: 24     Fields:    Translation:HumansCells
    138. Francis GM, Krohn EG, Woods KV, Buzaid AC, Grimm EA. Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Res. 1996 Jun; 6(3):191-201. PMID: 8819122.
      Citations: 4     Fields:    Translation:HumansCells
    139. Frederick MJ, Rodriguez LV, Johnston DA, Darnay BG, Grimm EA. Characterization of the M(r) 65,000 lymphokine-activated killer proteins phosphorylated after tumor target binding: evidence that pp65a and pp65b are phosphorylated forms of L-plastin. Cancer Res. 1996 Jan 01; 56(1):138-44. PMID: 8548753.
      Citations: 5     Fields:    Translation:HumansCells
    140. Anderson CM, Buzaid AC, Grimm EA. Interaction of chemotherapy and biological response modifiers in the treatment of melanoma. Cancer Treat Res. 1996; 87:357-80. PMID: 8886461.
      Citations:    Fields:    Translation:Humans
    141. Frederick MJ, Rodriguez LV, Johnston DA, Grimm EA. Tumor target binding induces phosphorylation of two M(r) 65,000 lymphokine-activated killer proteins. Cancer Res. 1996 Jan 01; 56(1):127-37. PMID: 8548752.
      Citations:    Fields:    Translation:HumansCells
    142. Jung FA, Buzaid AC, Woods KV, Ross M, Grimm EA. Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Cancer Surv. 1996; 26:251-65. PMID: 8783578.
      Citations:    Fields:    Translation:HumansCells
    143. Roussel E, Gingras MC, Grimm EA, Roth JA. High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. Cancer Immunol Immunother. 1995 Jul; 41(1):1-9. PMID: 7641214.
      Citations: 2     Fields:    Translation:HumansCells
    144. Tyler DS, Francis GM, Frederick M, Tran AH, Smith JL, Eton O, Ross M, Grimm EA, Ord??ez NG. Interleukin-1 production in tumor cells of human melanoma surgical specimens. J Interferon Cytokine Res. 1995 Apr; 15(4):331-40. PMID: 7627808.
      Citations: 6     Fields:    Translation:HumansCells
    145. Heaton KM, Grimm EA. Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2. Hum Immunol. 1995 Mar; 42(3):274-80. PMID: 7759316.
      Citations: 1     Fields:    Translation:HumansCells
    146. Zhang WW, Fujiwara T, Grimm EA, Roth JA. Advances in cancer gene therapy. Adv Pharmacol. 1995; 32:289-341. PMID: 7748797.
      Citations:    Fields:    Translation:Humans
    147. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994 Oct 05; 86(19):1458-62. PMID: 8089864.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    148. Buzaid AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res. 1994 Oct; 4(5):327-30. PMID: 7858418.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    149. Clayman GL, Stewart MG, Weber RS, el-Naggar AK, Grimm EA. Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol Head Neck Surg. 1994 Jul; 120(7):743-8. PMID: 8018327.
      Citations: 18     Fields:    Translation:HumansCells
    150. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994 May 01; 54(9):2287-91. PMID: 8162565.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    151. Heaton KM, Ju G, Grimm EA. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs. Ann Surg Oncol. 1994 May; 1(3):198-203. PMID: 7842289.
      Citations: 3     Fields:    Translation:HumansCells
    152. Koberda J, Przepiorka D, Moser RP, Grimm EE. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells. Lymphokine Cytokine Res. 1994 Apr; 13(2):139-45. PMID: 8061115.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    153. Fujiwara T, Mukhopadhyay T, Cai DW, Morris DK, Roth JA, Grimm EA. Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line. Int J Cancer. 1994 Mar 15; 56(6):834-9. PMID: 8119773.
      Citations: 7     Fields:    Translation:HumansCells
    154. Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol. 1994 Jan; 6(1):96-105. PMID: 8204698.
      Citations: 5     Fields:    Translation:Humans
    155. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 1993 Sep 15; 53(18):4129-33. PMID: 8395976.
      Citations: 18     Fields:    Translation:HumansCells
    156. Heaton KM, Grimm EA. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother. 1993 Sep; 37(4):213-9. PMID: 8348559.
      Citations: 7     Fields:    Translation:HumansAnimals
    157. Deen DF, Chiarodo A, Grimm EA, Fike JR, Israel MA, Kun LE, Levin VA, Marton LJ, Packer RJ, Pegg AE, et al. Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. J Neurooncol. 1993 Jun; 16(3):243-72. PMID: 7905510.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    158. Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 1993 Jun 01; 53(11):2597-602. PMID: 8495422.
      Citations: 28     Fields:    Translation:HumansCells
    159. Heaton KM, Ju G, Morris DK, Delisio K, Bailon P, Grimm EA. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Cell Immunol. 1993 Mar; 147(1):167-79. PMID: 8462109.
      Citations: 4     Fields:    Translation:HumansCells
    160. Fujiwara T, Loudon WG, Grimm EA. Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells. Lymphokine Cytokine Res. 1993 Feb; 12(1):45-8. PMID: 8096153.
      Citations:    Fields:    Translation:HumansCells
    161. Koberda J, Grimm EA, Moser RP. Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation. J Cancer Res Clin Oncol. 1993; 119(3):131-6. PMID: 8380285.
      Citations:    Fields:    Translation:HumansCells
    162. Lazenby AW, Roth JA, Owen-Schaub LB, Grimm EA. IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin). Cytokine. 1992 Nov; 4(6):479-87. PMID: 1337985.
      Citations: 1     Fields:    Translation:HumansCells
    163. Fujiwara T, Grimm EA. Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells. Cancer Res. 1992 Sep 15; 52(18):4954-9. PMID: 1387585.
      Citations:    Fields:    Translation:HumansCells
    164. Lagoo-Deenadayalan S, Lagoo AS, Hardy KJ, Grimm EA. Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor. Lymphokine Cytokine Res. 1992 Aug; 11(4):207-13. PMID: 1420599.
      Citations:    Fields:    Translation:HumansCells
    165. Fujiwara T, Grimm EA. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction. J Immunol. 1992 May 01; 148(9):2941-6. PMID: 1374105.
      Citations: 8     Fields:    Translation:Cells
    166. Owen-Schaub LB, Yonehara S, Crump WL, Grimm EA. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 1992 Mar; 140(1):197-205. PMID: 1371242.
      Citations: 65     Fields:    Translation:HumansCells
    167. List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res. 1992 Mar 01; 52(5):1123-8. PMID: 1737371.
      Citations: 18     Fields:    Translation:HumansCells
    168. Yang SC, Grimm EA, Roth JA. Combination immunotherapy for advanced lung cancer. J Natl Cancer Inst Monogr. 1992; (13):197-201. PMID: 1327033.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    169. Yang SC, Fry KD, Grimm EA, Roth JA. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy. J Immunother (1991). 1991 Oct; 10(5):326-35. PMID: 1790140.
      Citations:    Fields:    Translation:AnimalsCells
    170. Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. Cancer Res. 1991 Jul 15; 51(14):3669-76. PMID: 1648441.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    171. Grimm EA, Owen-Schaub L. The IL-2 mediated amplification of cellular cytotoxicity. J Cell Biochem. 1991 Apr; 45(4):335-9. PMID: 2045426.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    172. Grimm EA, Bruner JM, Carinhas J, Loudon WG, Owen-Schaub L, Steck PA, Moser RP, K?ppen JA. Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunol Immunother. 1991; 32(6):391-9. PMID: 1848799.
      Citations: 4     Fields:    Translation:HumansCells
    173. Owen-Schaub LB, de Mars M, Murphy EC, Grimm EA. IL-2 dose regulates TNF-alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes. Cell Immunol. 1991 Jan; 132(1):193-200. PMID: 2065356.
      Citations: 5     Fields:    Translation:HumansCells
    174. Crump WL, Owen-Schaub LB, Grimm EA. Molecular identification of the human tumor necrosis factor receptor on interleukin-2-stimulated peripheral blood lymphocytes. Cell Immunol. 1990 Nov; 131(1):150-8. PMID: 2171784.
      Citations:    Fields:    Translation:HumansCells
    175. Schantz SP, Clayman G, Racz T, Grimm EA, Liu FJ, Lavedan P, Taylor D, Pellegrino C, Savage H. The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1990 Nov; 116(11):1302-8. PMID: 2242261.
      Citations: 3     Fields:    Translation:HumansCells
    176. Yang SC, Owen-Schaub LB, Roth JA, Grimm EA. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha. Cancer Res. 1990 Jun 15; 50(12):3526-32. PMID: 2160321.
      Citations: 5     Fields:    Translation:HumansCells
    177. Irimura T, McIsaac AM, Carlson DA, Yagita M, Grimm EA, Menter DG, Ota DM, Clary KR. Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein production by human colon carcinoma cells. Cancer Res. 1990 Jun 01; 50(11):3331-8. PMID: 2334927.
      Citations: 11     Fields:    Translation:HumansCells
    178. Yang SC, Fry KD, Grimm EA, Roth JA. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha. Arch Surg. 1990 Feb; 125(2):220-5. PMID: 2137327.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    179. Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A, Grimm EA, Hong WK, Roth JA. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha. J Thorac Cardiovasc Surg. 1990 Jan; 99(1):8-12; discussion 12-3. PMID: 2152954.
      Citations: 7     Fields:    Translation:Humans
    180. Owen-Schaub LB, De Mars M, Murphy EC, Grimm EA. TNF-beta (lymphotoxin) strongly upregulates TNF-alpha gene expression in human peripheral blood lymphocytes. Lymphokine Res. 1990; 9(4):491-7. PMID: 1708843.
      Citations: 1     Fields:    Translation:HumansCells
    181. Wolf JA, Grimm EA. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes. Curr Opin Oncol. 1989 Dec; 1(2):249-57. PMID: 2489968.
      Citations:    Fields:    Translation:HumansCells
    182. Owen-Schaub LB, Crump WL, Morin GI, Grimm EA. Regulation of lymphocyte tumor necrosis factor receptors by IL-2. J Immunol. 1989 Oct 01; 143(7):2236-41. PMID: 2550551.
      Citations: 13     Fields:    Translation:HumansCells
    183. Yagita M, Itoh K, Tsudo M, Schaub LB, Platsoucas CD, Balch CM, Grimm EA. Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes. Cancer Res. 1989 Mar 01; 49(5):1154-9. PMID: 2783885.
      Citations: 8     Fields:    Translation:Humans
    184. Blacklock JB, Grimm EA. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system. Immunol Ser. 1989; 48:93-9. PMID: 2488328.
      Citations: 2     Fields:    Translation:HumansCells
    185. Yang SC, Owen-Schaub L, Grimm EA, Roth JA. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother. 1989; 29(3):193-8. PMID: 2543502.
      Citations: 12     Fields:    Translation:HumansCells
    186. Crump WL, Owen-Schaub LB, Grimm EA. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res. 1989 Jan 01; 49(1):149-53. PMID: 2783241.
      Citations: 23     Fields:    Translation:HumansCells
    187. Owen-Schaub LB, Grimm EA. Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines. Immunol Ser. 1989; 48:19-35. PMID: 2488321.
      Citations: 2     Fields:    Translation:HumansCells
    188. George RE, Loudon WG, Moser RP, Bruner JM, Steck PA, Grimm EA. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J Neurosurg. 1988 Sep; 69(3):403-9. PMID: 3261328.
      Citations: 10     Fields:    Translation:HumansCells
    189. Wolf JA, Grimm EA. Activated lymphocyte cytotoxicity: concepts and confusions. Ann Inst Pasteur Immunol. 1988 Jul-Aug; 139(4):435-8. PMID: 3048320.
      Citations:    Fields:    Translation:HumansCells
    190. Owen-Schaub LB, Gutterman JU, Grimm EA. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 1988 Feb 15; 48(4):788-92. PMID: 3257408.
      Citations: 52     Fields:    Translation:HumansCells
    191. Owen-Schaub LB, Loudon WG, Yagita M, Grimm EA. Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. Cell Immunol. 1988 Jan; 111(1):235-46. PMID: 3123071.
      Citations: 8     Fields:    Translation:HumansCells
    192. Grimm EA, Owen-Schaub LB, Loudon WG, Yagita M. Lymphokine-activated killer cells. Induction and function. Ann N Y Acad Sci. 1988; 532:380-6. PMID: 3140701.
      Citations: 1     Fields:    Translation:HumansCells
    193. Yagita M, Grimm EA. Current understanding of the lymphokine-activated killer cell phenomenon. Prog Exp Tumor Res. 1988; 32:213-26. PMID: 3131833.
      Citations: 3     Fields:    Translation:HumansCells
    194. Grimm EA, Crump WL, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schaub LB. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother. 1988; 27(1):53-8. PMID: 3260821.
      Citations: 16     Fields:    Translation:HumansCells
    195. Grimm EA. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors. Prog Clin Biol Res. 1987; 244:185-95. PMID: 3498948.
      Citations:    Fields:    Translation:HumansCells
    196. Jacobs SK, Parham CW, Holcomb B, Ikejiri B, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents. J Neurooncol. 1987; 5(1):5-10. PMID: 3037036.
      Citations: 2     Fields:    Translation:HumansCells
    197. Grimm EA. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochim Biophys Acta. 1986 Dec 17; 865(3):267-79. PMID: 3539198.
      Citations: 22     Fields:    Translation:HumansCells
    198. Lanza LA, Wilson DJ, Ikejiri B, Roth JA, Grimm EA. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells. J Immunol. 1986 Oct 15; 137(8):2716-20. PMID: 3489774.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    199. Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL, Grimm EA. Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies. Neurol Res. 1986 Jun; 8(2):81-7. PMID: 2875409.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    200. Jacobs SK, Melin G, Holcomb B, Parham CW, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells. Brain Res. 1986 May 07; 372(2):386-9. PMID: 3486696.
      Citations: 5     Fields:    Translation:AnimalsCells
    201. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg. 1986 May; 64(5):743-9. PMID: 3517250.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    202. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986 Apr; 46(4 Pt 2):2101-4. PMID: 3512079.
      Citations: 47     Fields:    Translation:HumansCellsCTClinical Trials
    203. Yagita M, Grimm EA. Inhibition of in vitro LAK generation by OK-432. Cancer Immunol Immunother. 1986; 23(3):207-13. PMID: 3491681.
      Citations: 2     Fields:    Translation:HumansCells
    204. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg. 1986 Jan; 64(1):114-7. PMID: 3001247.
      Citations: 24     Fields:    Translation:HumansCells
    205. Grimm EA, Jacobs SK, Lanza LA, Melin G, Roth JA, Wilson DJ. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy. Symp Fundam Cancer Res. 1986; 38:209-19. PMID: 3489259.
      Citations: 3     Translation:HumansAnimalsCells
    206. Grimm EA, Wilson DJ. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol. 1985 Sep; 94(2):568-78. PMID: 3928175.
      Citations: 14     Fields:    Translation:HumansCells
    207. Lotze MT, Rayner AA, Grimm EA. Problems with the isolation of lymphoid clones with reactivity to human tumors. Behring Inst Mitt. 1985 Aug; (77):105-14. PMID: 3936471.
      Citations: 1     Fields:    Translation:HumansCells
    208. Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst. 1985 Jul; 75(1):67-75. PMID: 2989604.
      Citations: 18     Fields:    Translation:HumansCells
    209. Grimm EA, Muul LM, Wilson DJ. The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL. Transplantation. 1985 May; 39(5):537-40. PMID: 3158107.
      Citations: 5     Fields:    Translation:HumansCells
    210. Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 1985 Mar 15; 55(6):1327-33. PMID: 3871657.
      Citations: 24     Fields:    Translation:HumansCells
    211. Grimm EA, Rayner AA, Wilson DJ. Human NK resistant tumor cell lysis is effected by IL-2 activated killer cells. Adv Exp Med Biol. 1985; 184:161-75. PMID: 2994409.
      Citations:    Fields:    Translation:HumansCells
    212. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30; 223(4643):1412-4. PMID: 6367046.
      Citations: 164     Fields:    Translation:HumansAnimalsCells
    213. Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer. 1984 Feb 15; 53(4):896-905. PMID: 6692292.
      Citations: 25     Fields:    Translation:HumansCells
    214. Grimm EA, Vose BM, Chu EW, Wilson DJ, Lotze MT, Rayner AA, Rosenberg SA. The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues. Cancer Immunol Immunother. 1984; 17(2):83-9. PMID: 6205746.
      Citations: 13     Fields:    Translation:Humans
    215. Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983 Oct 01; 158(4):1356-61. PMID: 6413638; PMCID: PMC2187385.
      Citations: 76     Fields:    Translation:HumansCells
    216. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med. 1983 Mar 01; 157(3):884-97. PMID: 6601174; PMCID: PMC2186968.
      Citations: 114     Fields:    Translation:HumansAnimalsCells
    217. Mazumder A, Grimm EA, Rosenberg SA. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. J Immunol. 1983 Feb; 130(2):958-64. PMID: 6848602.
      Citations: 13     Fields:    Translation:HumansCells
    218. Mazumder A, Grimm EA, Rosenberg SA. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunol Immunother. 1983; 15(1):1-10. PMID: 6603260.
      Citations: 18     Fields:    Translation:HumansCells
    219. Roth JA, Grimm EA, Osborne BA, Putnam JB, Davidson DD, Ames RS. Suppressive immunoregulatory factors produced by tumors. Lymphokine Res. 1983; 2(2):67-73. PMID: 6332246.
      Citations:    Fields:    Translation:HumansAnimals
    220. Bonavida B, Bradley TP, Grimm EA. Frequency determination of killer cells by a single-cell cytotoxic assay. Methods Enzymol. 1983; 93:270-80. PMID: 6408349.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    221. Grimm EA, Mazumder A, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor. Cell Immunol. 1982 Jul 01; 70(2):248-59. PMID: 6812964.
      Citations: 5     Fields:    Translation:HumansCells
    222. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 01; 155(6):1823-41. PMID: 6176669; PMCID: PMC2186695.
      Citations: 545     Fields:    Translation:HumansCells
    223. Roth JA, Grimm EA, Gupta RK, Ames RS. Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. J Immunol. 1982 May; 128(5):1955-62. PMID: 6460814.
      Citations: 14     Fields:    Translation:HumansCells
    224. Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res. 1982 Mar; 42(3):913-8. PMID: 7059990.
      Citations: 27     Fields:    Translation:HumansCells
    225. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981 Nov; 41(11 Pt 1):4420-5. PMID: 6975652.
      Citations: 126     Fields:    Translation:HumansCells
    226. Strausser JL, Mazumder A, Grimm EA, Lotze MT, Rosenberg SA. Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol. 1981 Jul; 127(1):266-71. PMID: 7195411.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    227. Targan S, Grimm E, Bonavida B. A single cell marker of active NK cytotoxicity: only a fraction of target binding lymphocytes are killer cells. J Clin Lab Immunol. 1980 Nov; 4(3):165-8. PMID: 7205938.
      Citations: 6     Fields:    Translation:HumansCells
    228. Roth JA, Grimm EA, Morton DL. A rapid assay for stimulation of human lymphocytes by tumor-associated antigens. Cancer Res. 1976 Sep; 36(9 pt.1):3001-10. PMID: 975069.
      Citations: 1     Fields:    Translation:HumansCells
    229. Grimm EA, Silver HK, Roth JA, Chee DO, Gupta RK, Morton DL. Detection of tumor-associated antigen in human melanoma cell line supernatants. Int J Cancer. 1976 May 15; 17(5):559-64. PMID: 1270174.
      Citations: 6     Fields:    Translation:HumansCells
    230. Roth JA, Golub SH, Grimm EA, Eilber FR, Morton DL. Effects of operation on immune response in cancer patients: sequential evaluation of in vitro lymphocyte function. Surgery. 1976 Jan; 79(1):46-51. PMID: 128842.
      Citations: 18     Fields:    Translation:HumansCells
    231. Roth JA, Golub SH, Grimm EA, Eilber FR, Morton DL. Effect of surgery on in vitro lymphocyte function. Surg Forum. 1974; 25(0):102-4. PMID: 4439131.
      Citations: 1     Fields:    Translation:HumansCells
    232. Harris TN, Grimm E, Mertens E, Ehrich WE. THE ROLE OF THE LYMPHOCYTE IN ANTIBODY FORMATION. J Exp Med. 1945 Jan 01; 81(1):73-83. PMID: 19871445; PMCID: PMC2135527.
      Citations: 20     Fields:    
    233. Reduction of pulmonary metastases following in vivo administration of anti-CD3, interleukin-2, and tumor necrosis factor-α in mice. Surgical Forum. 40:423-425.
    234. Enhancement of lymphokine-activated killer cell cytotoxicity with interleukin-2, tumor necrosis factor-alpha, and OKT3 against primary lung cancer targets. Surgical Forum. 39:454-456.
    235. Immunologic profile of a patient with dyskeratosis congenita. Immunology and Allergy Practice. 14:150-157.
    236. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clinical Cancer Research. 22:3016-3024.
    237. The single-cell assay in cell-mediated cytotoxicity. Immunology Today. 4:196-200.
    238. Dual roles of RNF2 in melanoma progression. Cancer Discovery. 5:1314-1327.
    239. Lymphokine-activated killer cell (LAK) lysis of human glioblastoma in vitro.
    240. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 6.
    241. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma. Melanoma Research.
    242. Braf mutations are associated with high levels of phosphorylated RKIP in melanoma cell lines. Forum on Immunopathological Diseases and Therapeutics. 2:189-194.
    243. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia (United States).
    244. Immunology comes full circle in melanoma while specific immunity is unleashed to eliminate metastatic disease, inflammatory products of innate immunity promote resistance. Critical Reviews in Oncogenesis. 21:57-63.
    245. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell and Melanoma Research. 28:357-359.
    246. Annals of the New York Academy of Sciences. 532:480-481.
    247. Regression of radiation- and chemotherapy-resistant non-small cell lung cancer treated with combination immunotherapy. Cancer Bulletin. 43:181-184.
    248. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (United States). 95.
    249. Biologic therapy for brain tumors. Cancer Bulletin. 43:117-126.
    250. [19] Frequency determination of killer cells by a single-cell cytotoxic assay. Methods. 93:271-280.
    251. A Rapid Assay for Stimulation of Human Lymphocytes by Tumor-associated Antigens. Cancer Research. 36:3001-3010.
    252. Hematopoietic Growth Factors and Cytokines. 605-619.
    253. Innate immune functions of microglia isolated from human glioma patients. Journal of Translational Medicine. 4.
    254. Biochemotherapy in the treatment of advanced melanoma. Drug News and Perspectives. 8:480-485.
    255. Interleukin-2 and cytotoxic lymphocyte therapy of primary and metastatic brain tumors. Fernstrom Foundation Series. 14:527-538.
    256. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell and Melanoma Research.
    257. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ (Journal of Investigative Dermatology (2015) 135 (2901) DOI. Journal of Investigative Dermatology. 135:2901.
    258. Uveal melanoma. Cancer.
    259. Demonstration of shared recognition and lysis of autologous and allogeneic fresh human tumors by cloned lymphokine-activated killer cells. Surgical Forum. VOL. 35:415-417.
    260. Erratum. Journal of Investigative Dermatology. 135:2775-2784.
    261. Studies on the immunotherapy of human gliomas using autologous lymphokine-activated killer cells. Surgical Forum. VOL. 36:504-506.
    262. Phase I clinical trial of infusion into cancer patients of autologous lymphocytes activated in vitro with lectins.
    263. Effects of low dose OKT3 induction on the antitumor immune response in cancer patients receiving interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF). Surgical Forum. 41:434-436.
    264. Hematopoietic Growth Factors and Cytokines.
    265. Biologic therapy for lung cancer. Cancer Bulletin. 43:100-108.
    266. Annals of the New York Academy of Sciences. 532:472-474.
    267. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Molecular Cancer Therapeutics. 15:2442-2454.
    268. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7:484-492.
    GRIMM's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (753)
    Explore
    _
    Co-Authors (91)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _